Cabio Biotech (Wuhan) Co Ltd
688089
Company Profile
Business description
Cabio Biotech (Wuhan) Co Ltd is a biotechnology company, engaged in Research & Development, production and sales of polyunsaturated fatty acids ARA, algae oil DHA and SA, natural B-carotene and other series products. The products are used in infant formula, dietary nutrition supplements and health Food, special medical formula food and other fields. The company's product sales area covers China, the United States, Europe, Australia, New Zealand, South Korea, and Southeast Asia.
Contact
No. 999, Gaoxin Avenue
East Lake New Technology Development Zone
Hubei Province
Wuhan430075
CHNT: +86 2767845289
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
595
Stocks News & Analysis
stocks
Avoid this overvalued ASX lithium producer
Why the market may be overpricing future earnings for this lithium producer.
stocks
Morningstar's verdict on SpaceX
Mark and Shani run through the business and what our analysts think about the IPO.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,988.30 | 61.40 | -0.68% |
| CAC 40 | 8,340.71 | 59.40 | -0.71% |
| DAX 40 | 24,893.58 | 246.11 | -0.98% |
| Dow JONES (US) | 51,666.84 | 45.87 | -0.09% |
| FTSE 100 | 10,428.85 | 9.00 | -0.09% |
| HKSE | 23,336.28 | 432.24 | -1.82% |
| NASDAQ | 25,587.04 | 579.56 | -2.21% |
| Nikkei 225 | 69,788.38 | 2,565.58 | -3.55% |
| NZX 50 Index | 13,435.77 | 10.28 | -0.08% |
| S&P 500 | 7,365.46 | 107.33 | -1.44% |
| S&P/ASX 200 | 8,787.00 | 48.10 | -0.54% |
| SSE Composite Index | 4,106.25 | 56.85 | -1.37% |